Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 128 Cr.
- Current Price ₹ 125
- High / Low ₹ 149 / 99.0
- Stock P/E 18.5
- Book Value ₹ 137
- Dividend Yield 2.38 %
- ROCE 6.83 %
- ROE 5.01 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.93 times its book value
Cons
- The company has delivered a poor sales growth of -7.28% over past five years.
- Company has a low return on equity of 8.05% over last 3 years.
- Earnings include an other income of Rs.9.22 Cr.
- Debtor days have increased from 110 to 133 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63.86 | 54.08 | 42.61 | 51.60 | 53.95 | 73.70 | 78.24 | 62.27 | 75.39 | 69.51 | 65.47 | 53.63 | |
| 56.80 | 51.16 | 36.62 | 42.57 | 44.78 | 52.31 | 53.52 | 51.30 | 59.24 | 56.86 | 54.19 | 51.39 | |
| Operating Profit | 7.06 | 2.92 | 5.99 | 9.03 | 9.17 | 21.39 | 24.72 | 10.97 | 16.15 | 12.65 | 11.28 | 2.24 |
| OPM % | 11.06% | 5.40% | 14.06% | 17.50% | 17.00% | 29.02% | 31.60% | 17.62% | 21.42% | 18.20% | 17.23% | 4.18% |
| 0.25 | 1.68 | 1.89 | 1.69 | 2.52 | 3.68 | 3.75 | 3.46 | 4.71 | 5.92 | 7.42 | 9.22 | |
| Interest | 1.11 | 0.29 | 0.08 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 3.34 | 1.76 | 1.87 | 1.85 | 1.84 | 1.74 | 1.72 | 1.79 | 1.77 | 1.94 | 1.99 | 2.00 |
| Profit before tax | 2.86 | 2.55 | 5.93 | 8.86 | 9.85 | 23.33 | 26.74 | 12.64 | 19.09 | 16.63 | 16.71 | 9.46 |
| Tax % | 32.87% | 3.53% | 48.06% | 33.86% | 27.41% | 24.73% | 25.24% | 26.11% | 25.72% | 26.40% | 25.73% | 26.74% |
| 1.93 | 2.47 | 3.08 | 5.86 | 7.15 | 17.56 | 19.98 | 9.33 | 14.17 | 12.24 | 12.41 | 6.94 | |
| EPS in Rs | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 11.94 | 12.11 | 6.77 |
| Dividend Payout % | 26.50% | 20.71% | 16.61% | 8.75% | 7.17% | 0.00% | 5.13% | 16.48% | 0.00% | 20.94% | 24.78% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -7% |
| 3 Years: | -11% |
| TTM: | -18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -20% |
| 3 Years: | -21% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -11% |
| 3 Years: | -12% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.23 | 10.23 | 10.23 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 |
| Reserves | 33.56 | 35.36 | 37.66 | 42.88 | 50.02 | 66.93 | 85.72 | 93.97 | 106.51 | 116.49 | 126.46 | 130.23 |
| 8.68 | 10.83 | 0.00 | 0.07 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 11.51 | 11.01 | 13.10 | 13.52 | 13.70 | 17.52 | 20.98 | 16.05 | 19.95 | 7.95 | 10.69 | 7.56 | |
| Total Liabilities | 63.98 | 67.43 | 60.99 | 66.72 | 74.01 | 94.70 | 116.95 | 120.27 | 136.71 | 134.69 | 147.40 | 148.04 |
| 28.98 | 28.40 | 26.57 | 19.84 | 19.15 | 17.67 | 17.93 | 16.63 | 16.61 | 17.90 | 16.48 | 18.88 | |
| CWIP | 0.38 | 0.33 | 0.33 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 34.62 | 38.70 | 34.09 | 46.88 | 54.86 | 77.03 | 98.49 | 103.64 | 120.10 | 116.79 | 130.76 | 129.16 | |
| Total Assets | 63.98 | 67.43 | 60.99 | 66.72 | 74.01 | 94.70 | 116.95 | 120.27 | 136.71 | 134.69 | 147.40 | 148.04 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.31 | 11.96 | 11.37 | 5.04 | 3.75 | 15.21 | 15.45 | 4.46 | 6.43 | 7.71 | 8.54 | 2.85 | |
| -0.98 | -1.34 | 0.60 | 6.29 | 0.63 | 2.04 | 0.42 | 3.16 | -3.12 | 3.94 | -0.62 | -8.95 | |
| -3.24 | 1.59 | -10.59 | -0.60 | -0.07 | -0.62 | -1.02 | -1.02 | -1.54 | -2.05 | -2.56 | -3.07 | |
| Net Cash Flow | -1.90 | 12.20 | 1.38 | 10.72 | 4.31 | 16.63 | 14.85 | 6.59 | 1.77 | 9.61 | 5.37 | -9.17 |
| Free Cash Flow | 1.33 | 10.82 | 11.33 | 10.25 | 2.61 | 14.95 | 12.95 | 4.58 | 4.68 | 4.48 | 7.84 | -1.41 |
| CFO/OP | 33% | 410% | 190% | 56% | 41% | 71% | 62% | 41% | 40% | 61% | 76% | 127% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90.65 | 106.71 | 81.12 | 68.05 | 68.81 | 64.04 | 79.91 | 96.25 | 106.90 | 100.40 | 95.45 | 132.99 |
| Inventory Days | 138.26 | 67.76 | 83.68 | 85.37 | 122.85 | 121.71 | 148.08 | 148.32 | 195.21 | 157.11 | 244.61 | 149.93 |
| Days Payable | 75.69 | 92.82 | 130.50 | 86.81 | 95.79 | 91.41 | 93.04 | 77.86 | 134.49 | 47.91 | 85.26 | 37.78 |
| Cash Conversion Cycle | 153.22 | 81.65 | 34.30 | 66.61 | 95.87 | 94.34 | 134.95 | 166.71 | 167.62 | 209.60 | 254.79 | 245.13 |
| Working Capital Days | 77.39 | 21.46 | 60.48 | 66.63 | 86.53 | 77.11 | 82.76 | 121.22 | 128.74 | 144.30 | 150.86 | 177.43 |
| ROCE % | 7.37% | 5.22% | 11.52% | 17.55% | 17.36% | 33.92% | 32.04% | 13.32% | 17.39% | 13.66% | 12.67% | 6.83% |
Insights
In beta| Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Husk (Fuel) Consumption MT |
|
|||||||||
| R&D as % of Turnover % |
||||||||||
| R&D Expenditure INR Lakhs |
||||||||||
| Total Permanent Employees Number |
||||||||||
| Reactor Capacity KL |
||||||||||
| Finished Goods Sales Volume MTS |
||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Newspaper Publication og Audited Financial Results for the 4th Quarter and Year Ended March 31, 2026
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Tyche Industries filed its FY2026 annual secretarial compliance report on 29 May 2026, noting full compliance.
-
Re-Appointment Of Internal Auditor And Cost Auditor
28 May - Board approved FY26 audited results, ₹3.50 dividend, and reappointed cost/internal auditors.
-
Corporate Action-Board approves Dividend
28 May - Board approved FY26 audited results, recommended Rs.3.50 dividend, and reappointed cost and internal auditors.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On May 28 2026
28 May - Board approved FY26 audited results, recommended Rs.3.50 final dividend, and reappointed cost and internal auditors.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe